Aviragen Therapeutics (AVIR) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street retreats as renewed Middle East strife hits sentiment; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 5% as Trump says US reinstating Iran naval blockade
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street retreats as renewed Middle East strife hits sentiment; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023 4:05 PM ESTPhase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23
Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV to start enrollment in 2Q23; initial results expected by 4Q23
AT-752 dengue program results and update
Conference call at 4:30 pm ET today
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Â Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today reported financial results for the fourth... More
